Skip to main content

Medical Oncology Clinic

The Institut Bordet Medical Oncology Clinic has a number of roles:

  • diagnosis and therapeutic care of patients with solid tumours
  • overseeing administration of cancer medication for in-patients and out-patients
  • monitoring patients during and after their treatment.

The Clinic takes a multidisciplinary approach. Therapeutic decisions are made in consultation with other specialist doctors and healthcare professionals involved in the patient’s care.
The aim is that patients should be monitored in all respects, including psychologically.

The Medical Oncology Clinic forms an integral part of the Department of Oncological Medicine. It is also very active in clinical research (particularly in the development of new medication) and translational research. At the Clinic, research is integrated into the care provided, enabling patients to benefit from the latest diagnostic and therapeutic advances, well before these become part of clinical routine.

Research projects

Project 1

AURORA Programme aimed at understanding the molecular characteristics of recurrent and metastatic breast cancer early in the evolution of metastatic disease.

Project 2

CHARACTERIZATION OF ENDOCRINE RESISTANT Luminal Breast Cancer using spatial transcriptomics AND epigenetic ANALYSIS. 
  • Project leaders : Christos Sotiriou, Françoise Rothé and Mattia Rediti
  • Collaborations : 
    - Dr François Fuks, Laboratory of Cancer Epigenetics, ULB-Cancer Research Center (U-CRC), Université libre de Bruxelles
    - Prof Lundeberg at the SciLife laboratory, Stockholm, Sweden
    - Dr Frédérick Libert, ULB/VUB Brightcore sequencing facility

Project 3

A phase 2 study to evaluate safety and anti-tumor activity of Avelumab in combination with Talazoparib in patients with BRCA or ATM mutant tumors

Project 4

  • Project leader : Thierry Berghmans
  • Collaborations : International clinical study
  • Funding (or) Support : EORTC

Project 5

AURA : Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers

Project 6

MIME-A Abémaciclib
Multiorgan Metabolic imaging response assessment of Abemaciclib

Our team

Head of the Medical Oncology Clinic
Pr A. Awada

Solid Tumours / New Innovative drugs
Pr A. AwadaDr Ph. AftimosDr N. Kotecki

Solid and RareTumours
Pr A. AwadaDr Ch. Jungels

Breast Oncology
Pr M. PiccartDr D. de Valeriola
Dr Ph. AftimosDr A. Gombos
Pr Ch. SotiriouDr E. de Azambuja
Dr M. IgnatiadisDr F. Lebrun 
Dr L. BuisseretDr L. Polastro
Dr M. Hanappe, Pr A. Drowart
Dr D. t’Kint de Roodenbeke

Dr L. Dal LagoPr Th. Pepersack (geriatrician)

Cervico-facial Oncology  
Dr Y. Lalami

Skin Tumour Oncology                
Dr J. Kerger / Pr A. Awada
Dr M. Suppa

Digestive Oncology / Gastroenterology / Endoscopy
Dr A. HendliszDr A. Deleporte
Dr F. Sclafani, Dr L. Shaza
Dr G. MachielsDr V. Ledouble

Dr F. Puleo

Gynaecological Oncology
Dr J. KergerDr L. Polastro
Dr F. LebrunPr A. Drowart

Thoracic Oncology
Pr Th. BerghmansDr I. Bold

Urogenital, Bone and Soft Tissue Oncology
Dr Th. Gil,
Dr Ch. Jungels (sarcomas)
Dr N. Martínez-Chanza (urogenital tumors)

Dr S. Sideris (urogenital tumors)

Oncological Day Hospital
Dr D. de Valeriola
Dr Y. Lalami, Dr L. Polastro

Dr D. t’Kint de Roodenbeke

Pr D. Razavi, Dr G. Stefos

Supportive and Palliative Cares / Pain Clinic
Pr D. Lossignol, Dr I. Libert, Pr A. Drowart (mobile unite)

Consultants :    
Pr J. Klastersky (internal medicine/oncology)
Pr B. Desmarez (gastroenterology/endoscopy)
Dr Z. El Ali (medical oncology)
Dr Y. Gökburun (gastroenterology/medical oncology)
Dr D. Levacq (medical oncology/oncogenetics)
Dr A. Lepida (gastroenterology/hepatology)
Dr H. Louis (gastroenterology/digestive functional disorders)
Dr F. Mana (gastroenterology/endoscopy)
Pr A. Van Gossum (endoscopy/gastroenterology/nutrition)

 Scientific publications

FOLFIRI as second-line treatment of metastatic biliary tract cancer patients.

Authors : Caparica R, Lengelé A, Bekolo W, Hendlisz A
Year : 2019
Journal : Autops Case Rep
Volume : 9
Pages : e2019087

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.

Authors : Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers FS, Schuehly U, Korde L, Azim HA Jr, Di Cosimo S, Tenglin RC, Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber Rd, de Azambuja E, Ignatiadis M
Year : 2019
Journal : Cancer
Volume : 125
Pages : 307-316

Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.

Authors : Lambertini M, Campbell C, Gelber Rd, Viale G, McCullough A, Hilbers F, Korde LA, Werner O, Chumsri S, Jackisch C, Wolff AC, Vaz-Luis I, Ferreira AR, Prat A, Moreno-Aspitia A, Piccart M, Loi S, de Azambuja E
Year : 2019
Journal : Breast Cancer Res Treat
Volume : 177
Pages : 103-114

Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients.

Authors : Plouznikoff N, Artigas C, Sideris S, Martinez Chanza N, Gil T, Peltier A, Flamen P
Year : 2019
Journal : Ann Nucl Med

Orthostatic blood pressure drop and cardiovascular and psychotropic medication dosages in acutely ill geriatric inpatients.

Authors : Paul J, Vaillant F, Vanden Bossche O, Pepersack T, Henrard S, Boland B
Year : 2019
Journal : Acta Clin Belg
Pages : 1-8